

## CLAIMS

1. A method for inducing immunosuppressive cells,  
which comprises culturing human cells with the use of a culture  
5 device having an affinity for protein.

2. The inducing method of Claim 1, wherein the culture  
device is previously coated with one or more cytokines ,or  
antibodies against surface antigens.

10

3. The inducing method of Claim 1, wherein the culture  
device is previously coated with two or more antibodies against  
surface antigens, each of said antibodies recognizing different  
epitope.

15

4. The inducing method of Claim 1, wherein human cells  
and one or more cytokines or antibodies against surface antigens  
are mixed.

20

5. The inducing method of Claim 1, wherein human cells  
and two or more antibodies against surface antigens, each of said  
antibodies recognizing different epitope, are mixed.

25

6. The inducing method of Claim 2, 3, 4 or 5, wherein  
the antibody against surface antigens is an anti-CD2 antibody or  
an anti-CD3 antibody.

7. The inducing method of Claim 2, 3, 4, 5 or 6, wherein the antibody against surface antigens is an anti-CD2 antibody, said anti-CD2 antibody binding to a site of CD2 that participates in the binding of LFA-3 to CD2.

5

8. The inducing method of Claim 2, 3, 4, 5 or 6, wherein the antibody against surface antigens is an anti-CD2 antibody, said anti-CD2 antibody binding to a site of CD2 other than a site of CD2 which participates in the binding of LFA-3 to CD2.

10

9. The inducing method of Claim 3 or 5, wherein two or more antibodies against surface antigens are anti-CD2 antibodies comprising a combination of one or more antibodies which bind to a site of CD2 that participates in the binding of LFA-3 to CD2 and one or more antibodies which bind to a site of CD2 other than the site of CD2 which participates in the binding of LFA-3 to CD2.

15

10. The inducing method of Claim 2, 3, 4, 5, 6, 7 or 8, wherein one antibody against surface antigens is the anti-CD2 antibody TS2/18.

20

11. The inducing method of Claim 2, 3, 4, 5, 6, 7 or 8, wherein one antibody against surface antigens is the F(ab)<sub>2</sub> fragment of the anti-CD2 antibody TS2/18.

25

12. The inducing method of Claim 2 or 4, wherein the cytokine is IL-2 or GM-CSF.

13. The inducing method of Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, wherein 0.5 to 10 % by volume of serum based on a culture medium is mixed in the culture.

14. The inducing method of Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, wherein no serum is mixed with the culture medium in the culture.

15. The inducing method of Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14, wherein a term of the culture ranges between 1 and 7 days.

16. The inducing method of Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15, wherein the culture device is made of material having an affinity for protein.

17. The inducing method of Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16, wherein the culture device is made of plastic material.

18. The inducing method of Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16, wherein the culture device is made of glass material.

19. The inducing method of Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18, wherein the culture device is a closed plane plate vessel or a closed vessel charged with

spherical fine-particles.

20. A culture device having an affinity for protein, which  
is used for inducing immunosuppressive cells by culturing human  
5 cells.

21. The culture device of Claim 20, wherein the device is  
previously coated with one or more cytokines or antibodies against  
surface antigens.

10

22. The culture device of Claim 20, wherein the device is  
previously coated with two or more antibodies against surface  
antigens, each of said antibodies recognizing different epitope.

15

23. The culture device of Claim 21 or 22, wherein the  
antibody against surface antigens is anti-CD2 antibody or anti-  
CD3 antibody.

20

24. The culture device of Claim 22 or 23, wherein one or  
more antibodies that recognize different epitope are the anti-CD2  
antibody TS2/18.

**IN THE CLAIMS:**

**Please cancel claims 1-19**

**Please amend the claims as follows:**

20. A culture device having an affinity for protein, which is used for inducing immunosuppressive cells by culturing human cells in said device.

21. The culture device of Claim 20, wherein prior to said culturing the device is [previously] coated with one or more cytokines and/or one or more antibodies against cell surface antigens.

22. The culture device of Claim 20, wherein prior to said culturing the device is [previously] coated with two or more antibodies against cell surface antigens, each of said antibodies recognizing a different epitope.

23. The culture device of Claim 21 [or 22], wherein said antibodies [the antibody] against cell surface antigens are [is] anti-CD2 antibodies [antibody] or anti-CD3 antibodies [antibody].

24. The culture device of Claim 23 or 25, wherein [one or more antibodies that recognize different epitope are] the anti-CD2 antibody is TS2/18 produced from hybridoma HB195 (ATCC Accession number HB-195).

**Please add new claim 25:**

25. The culture device of Claim 22, wherein said antibodies against cell surface antigens are anti-CD2 antibodies or anti-CD3 antibodies.

PRELIMINARY AMENDMENT  
Of Parent U.S. Appln. No. 09/254,170

**REMARKS**


This response follows an Office Action of September 26, 2000 withdrawing claims 20-25. Claims 1-19 are all the claims pending in the parent application.

Entry and consideration of this Amendment is respectfully requested.

Respectfully submitted,

SUGHRUE, MION, ZINN,  
MACPEAK & SEAS, PLLC  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3213  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Date: January 9, 2001

  
\_\_\_\_\_  
Susan J. Mack  
Registration No. 30,951